stars 1 stars 2 stars 3

Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging ("TCE") bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia, PA. For more information, visit www.contexttherapeutics.com.

Context Therapeutics Questions

The Context Therapeutics annual revenue was $4 million in 2026.

Martin Lehr is the CEO and Director of Context Therapeutics.

17 people are employed at Context Therapeutics.

Context Therapeutics is based in Philadelphia, Pennsylvania.

The NAICS codes for Context Therapeutics are [54, 541714, 5417, 54171, 541].

The SIC codes for Context Therapeutics are [28, 87, 283, 873].

Top Context Therapeutics Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users